Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …

Cancer immunotherapy has revolutionised cancer treatment, with immune checkpoint
blockade (ICB) therapy and adoptive cell therapy (ACT) increasingly becoming standard of …

Neoantigens arising from mutations in tumor DNA provide targets for immune-based
therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a …

Current success of immunotherapy in cancer has drawn attention to the subsets of TH cells
in the tumor which are critical for activation of anti-tumor response either directly by …

Simple Summary The relationship between the immune system and tumours is currently one
of the most studied topics in the field of cancer. Previously, it was thought that a tumour could …

Great advances in immune checkpoint blockade have resulted in a paradigm shift in patients
with lung cancer. Immune-checkpoint inhibitor (ICI) treatment, either as monotherapy or …

Background Immune checkpoint inhibitors (ICIs) have modest activity in ovarian cancer
(OC). To augment their activity, we used priming with the hypomethylating agent …

Immune checkpoint blocking antibodies are a cornerstone in cancer treatment; however,
they benefit only a subset of patients and biomarkers to guide immune checkpoint blockade …

Immunotherapy efficacy is limited in melanoma, and combinations of immunotherapies with
other modalities have yielded limited improvements but also adverse events requiring …